Answers are grounded in this paper and cite their sources.
Study improves knowledge and confidence in evaluating gMG severity and treatments, highlighting the need for targeted education.
To improve neurology clinicians’ knowledge, confidence, and behaviors in evaluating generalized myasthenia gravis (gMG) disease severity and integrating targeted treatments such as neonatal Fc receptor (FcRn) inhibitors into clinical decision-making.
No takes yet. Share an insight, caveat, or question.
Hegde et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: